• Completed

NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in NDMM

Updated: Jun 13

Phase 3 VISTA Study

phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone)


NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma


vista study

NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma


The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously untreated multiple myeloma.


Sponsor

Millennium Pharmaceuticals, Inc.


Collaborator

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

 

ClinicalTrials.gov Identifier: NCT00111319


Official Title: An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma

First Posted : May 20, 2005


Click here for details on ClinicalTrials.gov

 

Velcade: National Cancer Institute

Velcade: MedlinePlus Drug Information

Melphalan: National Cancer Institute

Melphalan: MedlinePlus Drug Information


Prednisone: National Cancer Institute

Prednisone: MedlinePlus Drug Information

 

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.

Ann Hematol. 2016 Dec

Click here for details

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

J Clin Oncol. 2013 Feb

Click here for details


Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

Eur J Haematol. 2011

Click here for details


Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.

Blood. 2010 Nov

Click here for details


Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

N Engl J Med. 2008 Aug

Click here for details

 

Locations

Multiple Locations

151 centers in 22 countries in Europe, North and South America, and Asia

United States

Spain

Sweden

Germany

Greece

Israel

Czech Republic

Italy

Russia

Poland

Argentina South America

Australia

New Zealand

Belgium

Hungary

Korea

Taiwan

United Kingdom

Ireland


Posts Archive